News - Rxlogix - Page 7 News - Rxlogix - Page 7

Search results for:

Top COVID Vaccine Pharma selects PV Signal, PV Reports and PV Analytics

RxLogix is pleased to announce that a leading COVID pharma company and provider of other therapies for the prevention and treatment of infectious diseases, has selected PV Signal, PV Reports and PV Analytics. The client was seeking a state-of-the art technology solution that would deliver a framework that supports integrated pharmacovigilance solutions to address signal […]

EU Headquartered Top 10 Global Pharma Selects RxLogix PV Compliance, Quality and Reporting Solutions

Another Top 10 pharma headquartered in France selects RxLogix for implementation of a new Reporting Environment supporting Pharmacovigilance business needs for: Standard Reports including Periodic Regulatory Reports (PBRER, DSUR, PADER, Japanese periodic reports) Ad-hoc Reports Interactive Dashboard Compliance Monitoring Quality Tracking Interfaces for downstream applications This will be a very large project with solution hosted […]

FDA is live with RxLogix PV Surveillance Platform (PV Reports, PV Signal, PV Analytics & PV Datahub)

FDA is live with the FAERS II program. The Center for Drug Evaluation and Research (CDER) & Center for Biologics Evaluation and Research (CBER) divisions at the U.S. Food and Drug Administration (FDA) are responsible for protecting the public health by ensuring the safety, efficacy, and security of human drugs and biological products. To perform […]

RxLogix End to End Safety Platform has been selected by a biopharmaceutical company to replace their existing safety platform

Biopharmaceutical company will go with RxLogix entire case management offering inclusive of the following RxLogix products: PV Case Management PV Gateway for electronic submissions PV Reports Aggregate Reporting PV Central for late case monitoring The company selected RxLogix PV Case Management Platform after a thorough evaluation inclusive of specific use cases including both AE forms, […]

RxLogix was selected by a European pharmaceutical company to replace their current safety database ARISg with RxLogix End to End Safety platform

Our new partner company develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for neurological disorders, oncology and respiratory diseases. The company’s products are marketed in over a hundred countries, and the Group’s own human pharmaceuticals sales organization covers all key European markets and a few Southeast Asian countries. In other markets […]